Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glucose Monitor Useful In Identifying Asymptomatic Diabetics, MiniMed Says

This article was originally published in The Gray Sheet

Executive Summary

MiniMed's planned introduction of a consumer version of its continuous home glucose monitor (CGMS) in 2001 is unlikely to result in the phasing-out the professional version introduced in July, given the recent physician debate about what separates a diabetic patient from a "normal" patient.

You may also be interested in...



MiniMed

Firm's Model 508 insulin infusion pumps distributed between Oct. 4 and Nov. 18, 1999 could have "a rare and minor software error" that could lead to a patient receiving an incorrect dosage, the firm announced Nov. 19. Notification containing programming instructions has been sent to all users who purchased the pump during the relevant time period and new systems contain an upgraded version of the software. FDA has been notified but no adverse event reports have been filed, according to the company

HCFA Insulin Pump Coverage Decision Estimates Annual Cost At $3,329

The annual cost of insulin therapy administered through a subcutaneous infusion pump is $3,329, the Health Care Financing Administration estimates in a Medicare national coverage decision for the devices in Type I diabetes announced Sept. 24. An effective date will be specified in an upcoming instruction to carriers.

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel